Takeda acquires Paradigm Therapeutics
Tokyo's Takeda Pharmaceutical Co Ltd will acquire Cambridge-based Paradigm Therapeutics Ltd for an undisclosed sum.
Paradigm will be renamed Takeda Cambridge Limited and Paradigm’s subsidiary in Singapore will be renamed Takeda Singapore Pte Limited.
Founded in 1999 by University of Cambridge researchers, Paradigm has established world-class target identification and validation capabilities based on genetic engineering and in vivo pharmacology. Using its capabilities, Paradigm has developed a promising pipeline of novel drug discovery targets and compounds in key areas of unmet medical need including pain, CNS disorders, prostate and breast cancer, diabetes, hyperlipidemia, and obesity.
With this merger, which replaces and builds upon Takeda and Paradigm’s 2005 CNS therapeutic area alliance, Paradigm’s technologies and researchers will be integrated into Takeda and will help to accelerate multiple scientific processes such as the validation of drug targets derived from genomic research, the creation of animal models reflecting the human pathologic conditions, and the optimization of drug candidates.
“Takeda have been an excellent partner in our CNS collaboration and this deal represents a logical and positive extension to that. The company looks forward to continuing with its drug discovery and development activities within the global reach and long term planning horizons of Takeda,” said Alastair Riddell, CEO of Paradigm.
“We are very excited with this deal, which will add to Takeda another research base equipped with the state-of-the-art technologies expected to further improve Takeda’s research efficiency,” said Yasuchika Hasegawa, President of Takeda. “We now have research functions in Japan, the U.S., Europe, and in Singapore where Paradigm has its subsidiary. This acquisition surely represents our initiatives for establishing global research infrastructures and for pursuing the world’s highest standard of productivity, which we believe will support enhancement of our R&D pipeline as source for future growth, and the realization of our goal to become a truly world-class pharmaceutical company.”
14th March 2007
